Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DiaSpax: randomized open-label comparison of empagliflozin, pioglitazone, and semaglutide in type 2 diabetes
2024-513416-98-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Jan 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Empagliflozin arm, Pioglitazone arm and Semaglutide arm (3 arms). Primary endpoint: Basal and maximal isoprenaline-stimulated lipolysis in isolated adipocytes. Planned start Jan 2023; status: authorised.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-513416-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513416-98-00.